HIGHLIGHTS
- who: . and colleagues from the University of Parma, Italy have published the research work: Palbociclib impairs the proliferative capacity of activated T cells while retaining their cytotoxic ef cacy, in the Journal: (JOURNAL)
- what: The aim of this study was to examine the impact of palbociclib and fulvestrant alone or in combination on CD3+ T_cells and novel emerging T_cell-based cancer immunotherapies.
- how: The authors used the switchable UniCAR system (Bachmann 2019) that is also currently under clinical investigation in a phase I clinical trial (NCT04230265). The authors examined the influence of palbociclib . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.